Ansun Biopharma of San Diego closed an $80 million Series B funding from China investors to advance its innovative antiviral. The company’s lead product is a first-in-class recombinant sialidase protein that removes sialic acid from the surface of airway epithelial cells, preventing the virus from entering the host. In the US, the FDA has granted the candidate Fast Track Eligibility and Breakthrough Therapy to treat lower respiratory tract infections caused by parainfluenza virus (PIV) in immunodeficient patients. It is also thought to be effective against resistant flu strains.
Source: China Biotoday